达格列净对射血分数保留或轻度降低心衰患者健康状况的影响
DELIVER试验预设分析纳入5795例有症状的HFmrEF/HFpEF患者,随机接受达格列净10mg或安慰剂。达格列净在8个月时改善KCCQ总分及各领域评分,且基线症状负担越重,心血管死亡/心衰恶化的获益越明显。
要点
- 达格列净改善HFmrEF/HFpEF患者8个月时的KCCQ症状、身体限制、临床和总体评分。
- 基线症状负担越重,达格列净降低心血管死亡/心衰恶化的获益越显著。
- 达格列净组KCCQ各领域恶化比例更少、改善比例更多。
核心结论
- 达格列净改善HFmrEF/HFpEF患者所有KCCQ领域评分及临床意义改善比例。
- 基线症状负担更重的患者临床获益更明显。
研究设计与样本
- DELIVER试验预设分析,随机分配有症状HFmrEF/HFpEF患者至达格列净10mg或安慰剂。
- 5795例患者有基线KCCQ,中位KCCQ-TSS为72.9,按KCCQ-TSS三分位分层。
主要发现
- 达格列净降低心血管死亡/心衰恶化在基线KCCQ-TSS最低三分位HR 0.70(95%CI 0.58-0.84),中三分位HR 0.81(95%CI 0.65-1.01),高三分位HR 1.07(95%CI 0.83-1.37),Pinteraction=0.026。
- 8个月时达格列净组KCCQ-TSS、PLS、CSS、OSS分别较安慰剂高2.4、1.9、2.3、2.1分,P均<0.001。
- 达格列净对KCCQ-TSS的改善不受EF影响(Pinteraction=0.85)。
- 8个月时达格列净组KCCQ各领域恶化比例更少、改善比例更多。
临床怎么用
- 对HFmrEF/HFpEF患者,达格列净可改善症状相关健康状况,基线症状负担重者可能获益更大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) experience a high burden of symptoms, physical limitations, and poor quality of life; improving health status is a key goal of management. OBJECTIVES: In a prespecified analysis of the DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure) trial, we examine effects of dapagliflozin on health status using the Kansas City Cardiomyopathy Questionnaire (KCCQ). METHODS: The DELIVER trial randomized patients with symptomatic HFmrEF/HFpEF to dapagliflozin 10 mg or placebo. KCCQ was evaluated at randomization, 1, 4, and 8 months; KCCQ Total Symptom Score (TSS) was a key secondary endpoint. Patients were stratified by KCCQ-TSS tertiles; Cox models examined effects of dapagliflozin on clinical outcomes. We evaluated the effects of dapagliflozin on KCCQ-TSS, Physical Limitations (PLS), Clinical Summary (CSS), and Overall Summary (OSS) domains. Responder analyses compared proportions of dapagliflozin vs placebo-treated patients with clinically meaningful changes in KCCQ. RESULTS: A total of 5,795 patients had baseline KCCQ (median KCCQ-TSS 72.9). The effects of dapagliflozin on reducing cardiovascular death/worsening HF appeared more pronounced in patients with greater baseline symptom burden (lowest-to-highest KCCQ-TSS tertile: HR: 0.70 [95% CI: 0.58-0.84]; 0.81 [95% CI: 0.65-1.01]; 1.07 [95% CI: 0.83-1.37]; Pinteraction = 0.026). Dapagliflozin improved KCCQ-TSS, -PLS, -CSS, and -OSS at 8 months (2.4, 1.9, 2.3, and 2.1 points higher vs placebo; P < 0.001 for all). Dapagliflozin-treated patients experienced improvements in KCCQ-TSS regardless of EF (Pinteraction = 0.85). Fewer dapagliflozin-treated patients had deterioration, and more had improvements in all KCCQ domains at 8 months. CONCLUSIONS: The clinical benefits of dapagliflozin in HFmrEF/HFpEF appear especially pronounced in those with greater baseline symptom impairment. Dapagliflozin improved all KCCQ domains and the proportion of patients experiencing clinically meaningful changes in health status. (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure [DELIVER]; NCT03619213).
引用
- Kosiborod MN, Bhatt AS, Claggett BL, et al. Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction. J Am Coll Cardiol. 2022. PMID: 36526515. doi:10.1016/j.jacc.2022.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。